Powder: -20°C for 3 years
In solvent: -80°C for 2 years
GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.
Description | GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential. |
Targets&IC50 | PI4K2B:<5 (pIC50), PI4KB:7.2-7.7 (pIC50), PI4K2A:<5 (pIC50), PI4KA:8.5-9.8 (pIC50) |
In vitro | GSK-A1 is a selective?type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα)?inhibitor with a?pIC50?of 8.5-9.8[3]. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2[3]. |
Molecular Weight | 574.63 |
Formula | C29H27FN6O4S |
CAS No. | 1416334-69-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK-A1 1416334-69-4 PI3K/Akt/mTOR信号通路 蛋白酶体 微生物学 HCV Protease PI4K PtdIns(4,5)P2 PI4KIIIα inhibit Hepatitis C virus GSK A1 Phosphatidylinositol 4 kinases PtdIns(4)P phosphatidylinositol 4-kinase PI4KA HCV Inhibitor PI4 kinases GSKA1 GSK-A-1 inhibitor